CD34

CD34  Test Purpose

This Test detects the presence of CD34 (Cluster of Differentiation 34), a cell surface protein expressed on hematopoietic stem cells, progenitor cells, endothelial cells, and certain tumor cells. The test is commonly performed using Immunohistochemistry (IHC) on tissue samples or flow cytometry on blood or bone marrow samples. It plays a crucial role in diagnosing and classifying hematological malignancies, evaluating vascular tumors, and identifying stem cell populations.

Healthcare providers commonly recommend the CD34 Test for individuals with suspected leukemia, lymphoma, bone marrow disorders, unexplained abnormal blood counts, vascular tumors, or soft tissue masses. It is also widely used during the evaluation of acute leukemias, particularly Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), where CD34 expression helps identify immature blood-forming cells (blasts).

Furthermore, the CD34 Test assists in identifying hematopoietic stem cells before stem cell transplantation and is valuable in assessing bone marrow cellularity and regeneration. In surgical pathology, CD34 serves as an important marker for vascular tumors, including hemangioma, angiosarcoma, and solitary fibrous tumors, while also helping distinguish these tumors from other soft tissue neoplasms. However, CD34 expression is not specific to a single disease, and abnormal results should always be interpreted alongside clinical findings, microscopic examination, and additional laboratory investigations.

The CD34 Test is often performed together with CD31, CD117 (c-KIT), CD45, CD3, CD20, CD19, CD38, MPO (Myeloperoxidase), TdT, Flow Cytometry Immunophenotyping, Bone Marrow Examination, and other immunohistochemistry markers to provide a comprehensive evaluation of blood disorders and tumors.

This Test is Recommended for Individuals:

• Patients with suspected leukemia or lymphoma.
• Individuals with abnormal blood counts or bone marrow disorders.
• Patients undergoing evaluation for Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL).
• Individuals with suspected vascular or soft tissue tumors.
• Patients being evaluated for hematopoietic stem cell transplantation.
• Individuals requiring immunophenotyping or tumor classification.
• Patients advised by their hematologist, oncologist, or pathologist to undergo CD34 testing.

FAQs

1. What is the CD34 Test used for?

This Test detects CD34 protein on stem cells, endothelial cells, and certain tumor cells. It is used to diagnose leukemia, classify tumors, identify hematopoietic stem cells, and evaluate vascular tumors.

2. Is fasting required for the CD34 Test?

No, fasting is generally not required. The test is performed on a blood sample, bone marrow sample, or tissue biopsy, depending on the clinical indication. Follow any preparation instructions provided by your healthcare provider.

3. What does a positive CD34 result mean?

A positive CD34 result indicates the presence of CD34-expressing cells, such as hematopoietic stem cells, immature blood cells (blasts), endothelial cells, or certain tumor cells. The significance depends on the type of sample, the patient's clinical condition, and the results of other diagnostic tests. Your healthcare provider or pathologist will interpret the findings to determine the underlying diagnosis and guide appropriate treatment.